JP2019523687A - 放射線治療に用いる装置 - Google Patents
放射線治療に用いる装置 Download PDFInfo
- Publication number
- JP2019523687A JP2019523687A JP2019506339A JP2019506339A JP2019523687A JP 2019523687 A JP2019523687 A JP 2019523687A JP 2019506339 A JP2019506339 A JP 2019506339A JP 2019506339 A JP2019506339 A JP 2019506339A JP 2019523687 A JP2019523687 A JP 2019523687A
- Authority
- JP
- Japan
- Prior art keywords
- irradiation
- ultraviolet
- radiation
- wavelength
- module
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 143
- 230000009471 action Effects 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 60
- 230000001678 irradiating effect Effects 0.000 claims abstract description 25
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 230000005855 radiation Effects 0.000 claims description 76
- 238000011282 treatment Methods 0.000 claims description 69
- 239000002245 particle Substances 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000024908 graft versus host disease Diseases 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 11
- 206010033645 Pancreatitis Diseases 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000005251 gamma ray Effects 0.000 claims description 3
- 230000005865 ionizing radiation Effects 0.000 abstract description 75
- 230000008569 process Effects 0.000 abstract description 25
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 85
- 210000004027 cell Anatomy 0.000 description 65
- 108020004414 DNA Proteins 0.000 description 48
- 230000005778 DNA damage Effects 0.000 description 26
- 231100000277 DNA damage Toxicity 0.000 description 26
- 238000011160 research Methods 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 24
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 21
- 230000006378 damage Effects 0.000 description 19
- 238000001126 phototherapy Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 238000002591 computed tomography Methods 0.000 description 14
- -1 HZE ions Chemical class 0.000 description 13
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 13
- 239000003504 photosensitizing agent Substances 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 11
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 10
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229960004469 methoxsalen Drugs 0.000 description 9
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 8
- 201000004681 Psoriasis Diseases 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 7
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 7
- 230000005670 electromagnetic radiation Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- CRMBVHJMQTYDMJ-QZTJIDSGSA-N furanocoumarin Natural products CC(C)OC(C)(C)[C@H](O)COc1c2C=CC(=O)Oc2c(OC[C@@H](O)C(=C)C)c3occc13 CRMBVHJMQTYDMJ-QZTJIDSGSA-N 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 239000010836 blood and blood product Substances 0.000 description 6
- 229940125691 blood product Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000033616 DNA repair Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229960002045 bergapten Drugs 0.000 description 5
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000254 damaging effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- ZCJLOOJRNPHKAV-ONEGZZNKSA-N (e)-3-(furan-2-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CO1 ZCJLOOJRNPHKAV-ONEGZZNKSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 125000000422 delta-lactone group Chemical group 0.000 description 4
- 238000002059 diagnostic imaging Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 231100001074 DNA strand break Toxicity 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035474 group of disease Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000006552 photochemical reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AZNIMZMJKRIGPL-UHFFFAOYSA-N 2,3,4,6-tetrahydrochromen-7-one Chemical compound O1CCCC2=CCC(C=C12)=O AZNIMZMJKRIGPL-UHFFFAOYSA-N 0.000 description 2
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 description 2
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000546188 Hypericum Species 0.000 description 2
- 244000179970 Monarda didyma Species 0.000 description 2
- 235000010672 Monarda didyma Nutrition 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000024340 acute graft versus host disease Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000033590 base-excision repair Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- VJBCBLLQDMITLJ-UHFFFAOYSA-N chromen-7-one Chemical compound C1=COC2=CC(=O)C=CC2=C1 VJBCBLLQDMITLJ-UHFFFAOYSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000020520 nucleotide-excision repair Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000037911 visceral disease Diseases 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- KNJUOEDHHOTPLA-YIUNNBJSSA-N (15S,16S,18R)-4,16-dihydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-3,5-dione Chemical compound C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)N(O)C(=O)c4c4c5ccccc5n2c4c13 KNJUOEDHHOTPLA-YIUNNBJSSA-N 0.000 description 1
- CFQAMEDTKHNQTP-UHFFFAOYSA-N 3-(ethoxycarbonyl)psoralen Chemical compound C1=C2OC(=O)C(C(=O)OCC)=CC2=CC2=C1OC=C2 CFQAMEDTKHNQTP-UHFFFAOYSA-N 0.000 description 1
- 241000722941 Achillea Species 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- 230000005461 Bremsstrahlung Effects 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010010737 Ceruletide Proteins 0.000 description 1
- 241000252506 Characiformes Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000089742 Citrus aurantifolia Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930193323 Ficusin Natural products 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 108700011498 Glucocorticoid Receptor Deficiency Proteins 0.000 description 1
- 241000125184 Heracleum Species 0.000 description 1
- 241000117544 Heracleum grossheimii Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023138 Jaundice neonatal Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 238000009193 PUVA therapy Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 240000004370 Pastinaca sativa Species 0.000 description 1
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000920340 Pion Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241001661355 Synapsis Species 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010060875 Uraemic pruritus Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- USOCNTXXEFZGCT-UHFFFAOYSA-N benzene pyran-2-one Chemical compound C1=CC=CC=C1.O=C1C=CC=CO1 USOCNTXXEFZGCT-UHFFFAOYSA-N 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- DBMJZOMNXBSRED-OQLLNIDSSA-N bergomottin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC/C=C(C)/CCC=C(C)C DBMJZOMNXBSRED-OQLLNIDSSA-N 0.000 description 1
- 125000003180 beta-lactone group Chemical group 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229930190815 caerulein Natural products 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 1
- 229960001706 ceruletide Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000000457 gamma-lactone group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000026352 glucocorticoid resistance Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical group [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000005362 photophoresis Methods 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/10—Ultraviolet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N2005/0602—Apparatus for use inside the body for treatment of blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1048—Monitoring, verifying, controlling systems and methods
- A61N5/1049—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam
- A61N2005/1061—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using an x-ray imaging system having a separate imaging source
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1091—Kilovoltage or orthovoltage range photons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
(I)天然の太陽光を用いた死海光療法や「PUVA sun」と呼ばれる太陽光を用いた光化学療法。
(II)UVA光源を単独で用いる、またはBB−UVBやNB−UVB等の他の光源を併用することにより、光源から人工光を照射する方法。
(III)光増感光線療法、系統的投与に基づくPUVA(ソラーレンの経口投与とUVA照射を組み合わせた方法など)、局所的投与に基づくPUVA(ソラーレンの局所投与とUVA照射を組み合わせた方法など);沐浴式のPUVA。
複数の亜原子粒子が放射性崩壊によって生成された際には、これらは紙面や皮膚によって遮蔽可能である。
電離作用を有する放射線を照射するように構成された電離作用発生モジュールと、
電源と、ユーザ操作用のインターフェース機能を提供する操作入力用制御部と、
を備えている。
また、この装置は、UVA波長、UVB波長およびUVC波長のうちの何れか一つ以上の波長領域に対応する紫外線の照射を行う紫外線照射モジュールをさらに備えており、
前記電離作用発生モジュールと前記紫外線照射モジュールは、両者同時に又は片方ずつ交互に切り替えながら電離作用を有する前記放射線の照射と前記紫外線の照射を行い、前記電離作用発生モジュールは、少なくとも100ナノメートルより短い波長で放射線を照射する、ことを特徴とする。
電離作用を有する前記放射線の前記電離作用発生モジュールによる照射と前記紫外線照射モジュールによる前記紫外線の照射を両者同時に又は片方ずつ交互に切り替えながら一定の時間にわたって行う第2工程と、
を備え、前記電離作用発生モジュールは、少なくとも100ナノメートルより短い波長で前記放射線を照射するように構成されている。
上述した装置を提供する第1工程と、
表面を照射すべき対象物を照射位置に配置する第2工程と、
1分間から48時間の範囲内の継続時間幅にわたって照射を行う工程であって、前記装置が備える2つのモジュールによるそれぞれの照射を、両者同時に又は片方ずつ交互に切り替えながら行う第3工程と、を備える方法であり、任意付加的に実行され得る工程として、
上述した照射を繰り返し行う工程と、上述した照射を行う前に、または断続する照射の合間において、光化学活性を有する1種類以上の化合物を前記対象物に塗布する工程と、をさらに備えている。
本発明はさらに、放射線核様体医療技術と併用する形で使用されてもよい。
皮膚組織あるいは内臓の器官(肝臓あるいは胃腸のチャネル)が急性移植片対宿主病を患っている患者を治療対象として、皮膚組織の移植片対宿主性移植片病への光化学療法を併用する形で照射処置が行われ、内臓の移植片対宿主病が治癒したか否かについて評価された。28人の患者が断続的な照射区間に分割して行う全身照射により治療され、骨髄移植と共にシクロホスファミドの投与が併用された処置から35(13−77)メジアン値(最小値−最大値)で表される日数だけ経過した後に光化学療法を開始する。5人の患者について条件付けをせずに全身照射を行う代わりに、骨髄移植の前にブスルファンとシクロホスファミドの投与を受けた。骨髄移植後に26(13−68)で表される日数だけ経過した後に、光化学療法を開始した。
試験用に適合化されたDNA損傷を用いて致死性の急性呼吸窮迫症候群(ARDS)に対する効果を概念的に実証することを目的とした試験
<背景>ARDSは腹部手術と膵臓炎に次いて共通の致死率が高い一般的な合併症である。ARDSはTh17細胞の活性化と結合され、膵臓炎および膵臓癌の主要因であるとも確認された(Chepalla 2016、Oiva 2010年)。アポトーシスによる細胞死は、耐性を誘発する因子として慣用されてきており、DNAが損傷に至る経路は新医薬品の発見のために調査対象となり、耐性を誘発させる対象となる(Neves−Costa AおよびLuis F Moitaによる2016年の研究報告)。特に、光化学療法はTh17を減少させ、ビタミンDの生成を誘発し、Th17とビタミンDの両者はARDS(Furuhashi 2013年、サルビアの葉、Li Q、Li JT 2005 2016 2010)を軽減する可能性がある。線量が低い照射処理と光化学療法の組み合わせには相乗効果が生体外で引き起こされる。個別の報告書は低い線量での照射および光化学療法を示唆しているが、両者はCD 4コンパートメント(Gridley 2009、Singh 2010年)に影響する可能性がある。合併症と副次的に関係するARDSを持った患者が光化学療法の追加による臨床効果に加えてコンピューター断層撮影(CT)装置内の照射領域を通ることで、2重螺旋鎖構造を有するDNAが画像診断用装置(CT用)からの照射により損傷した場合のDNA修復時間が半分の10分〜30分以下に短縮された。
[1] Liu S et al. Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to lung injury, 2016 Scientific Report Nov 16. 1-8.
[2] Shi-Ping D. A mouse model of severe pancreatitis induced with caerulein and lipopolysaccharide World J Gastroenterology 2003;9(3):584-589.
[3] Gugliemotti A., Benzydamine protection in a mouse model of endotoxemia, Inflammation res. 46 (1997) 332-335.Zhou M-T., Acute Lund Injury and ARDS in acute Pancreatitis: Mechanisms and potential intervention 2010 May 7; 16(17): 2094-2099.
[4] Iclozan C., T helper 17 are sufficient but not necessary to induce Acute Graft-versus-host disease Kappel W. IL-17 contributes to CD4-mediated graft-versus-host disease., 2009 Blood, Jan 22; 113(4): 945-954.
[5] Mauermann N.,et al. Interferon-gamma regulates idiopathic pneumonia syndrome, a 30 Th17+CD4+ T-cell mediated Graft-versus-host disease. 2008 Pp 379-388, 2008Chellappa S. et al.
[6] Regulatory T cells that co-express ROR-gamma-t and FOXP3 are pro-inflammatory and immunosuppressive and expand in pancreatic cancer 2016, VOL. 5, NO. 4.
[7] Oiva et al. Acute pancreatitis with organ dysfunction associates with abnormal blood lymphocyte signalling: controlled laboratory study 2010, Critical Care 14: R207Li Q., et al. 35 Resolution of acute respiratory distress syndrome through reversing the imbalance of Treg/Th17 by targeting the cAMP pathway Mol Med Rep. 2016 Jul; 14(1): 343-8.
[8] Li JT et al. Unexpected Role for Adaptive alpha-beta Th17 Cells in Acute respiratory distress syndrome J Immunol 205 jul 1;195(1):87-95.
[9] Sage RJ and Lim HW. UV-based therapy and vitamin D Dermatoll Ther. 2010 Jan-Feb 40 23(1):72-81.
測定はRTIピラニアメッド線量プローブ(外部検出器)を電位計として構成した上で測定を行った。プログラムとして、Ocean, 2014, ver. 2016−12−07. 242.を使用した。照射源としてGE C−arm Stenoscopを使用した。Somaテクノロジー社製のUVA紫外線照射用およびX線照射用のモジュール・チューブを互いに90度の角度を成すような空間配置で(図1)取り付けて装置を構成した。イオン化放射の長さを10秒間として測定を行った。
Opti 150/30/50HC−100にVerifix UVA−star 500(230 V / 18W)を組み合わせて500mmの寸法を有するX線管を組み立て、
紫外光はディジタル式の紫外線放射計を用いて測定し、スペクトル感度は280ナノメートル〜400ナノメートル、ピーク・レスポンスは370ナノメートル、精度は±5%である(Bohle,art no BO 55 003 00)。Verifix UVA starは照射対象物の配置エリアにおける照射強度が3.6−3.8(mW/cm2)となる距離だけ離れた設置場所で組み立てられた。FACSチューブ・プラスチックの上での実効的な線量低下率を測定した結果は50%であった。
CT コンピューター断層撮影画像診断法
UV 紫外線または紫外光/照射波長の種別を表す符号(タイプA〜C)が続く
PUVA UVAを用いて行われ、患者や動物にソラーレンを経口投与した後に、紫外線により皮膚を照射する
PUVA sun 天然の太陽光を光源とする
GVHD 移植片対宿主病
[1] Banath P. 1998 “Rejoining of DNA single- and double-strand breaks in human white blood cells exposed to ionization irradiation”, International Journal of Irradiation Biology, Vol. 73 No. 6, p. 649-660
Barry S. et al. 1976 “Molecular and genetic basis for furocoumarin reactions”, Mutation Research, Vol. 39 p. 29-74.
[2] Cardo C. et al. 2007 “Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light”, Transfusion and Apheresis Science Vol. 37 p. 131–137.
[3] Heering W. 2004: “UV-sources – Basics, Properties and Applications”, IUVA NEWS, Vol. 6, No. 4, p. 7-13.
[4] Hiraku Y. et al. 2007 “Photosensitized DNA Damage and its Protection via a Novel Mechanism”, Photochemistry and Photobiology Vol 83 p. 205–212.
[5] Kitamura N. et al 2005 “Molecular aspects of furocoumarin reactions: Photophysics, photochemistry, photobiology, and structural analysis, Journal of Photochemistry and Photobiology” Photochemistry Reviews Vol. 6 p. 168–185.
[6] Kumar C. et al. 2016 “Relevance of radiobiological concepts in radionuclide therapy of cancer”, International Journal of Irradiation Biology, DOI: 10.3109/09553002.2016.1144944.
[7] Nocentini S. 1999 “Rejoining kinetics of DNA Single- and Double stranded breaks in normal and DNA ligase-deficient cells after exposure to Ultraviolet C and gamma irradiation: An evaluation of ligating activities involved in different DNA repair processes”, Irradiation 30 research Vol. 151, p. 423-432.
[8] Parrish J. A. et al. 1974: ”Photochemotherapy of psoriasis with oral methoxasalen and long-wave ultraviolet light”, The New England Journal of Medicine Vol. 291 p. 1207-1211.
[9] Parrish J. A., Jaenicke K. F. 1981: “Action spectrum for phototherapy of psoriasis”, J Invest Dermatology Vol. 75 No. 5 p. 359-362.
[10] Pathak M. A. et al. 1951: “The Presently Known Distribution of Furanocoumarins (Psoralens) in plants”, Journal of Investigative Dermatology p. 225-239.
[11] Pourakbar M. et al. 2016 “Homogenous VUV advanced oxidation process for enhanced Degradation and mineralization of antibiotics in contaminated water”, Ecotoxicology and Environmental Safety Vol . 125 p. 72–77.
[12] Seghatchian J. 2012 “Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system – An update” Transfusion and Apheresis Science vol. 46 p. 221–229.
[13] Singh T. P. et al 2011 “8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder” J Immunol; vol. 184 no. 12 p. 7257-67.
[14] Srinivas C. R. and Pai S. 1997: ”Psoralens”, Indian J Dermatol Venereol Leprol Vol. 63 p. 276-287.
Stern R. S. 2007: “Psoralen and Ultraviolet A Light Therapy for Psoriasis”, The New England Journal of Medicine Vol. 357 No. 7 p. 682-690.
[15] Wiskeman A. 1978: “UVB-phototherapy of psoriasis using a standing box developed for 10 PUVA-therapy”, Z Hautkr Vol. 53, No. 18, 633-636.
[16] Wolf P. et al. 2016 “Serotonin signaling is crucial in the induction of PUVA-induced systemic suppression of delayed type hypersensitivity but not local apoptosis or inflammation of the skin”, Exp. Dermatology, Epub ahead of print.
[17] Wu J. et al. 2009 “Optimization of the comet assay for the sensitive detection of PUVA-15 induced DNA interstrand cross-links”, Mutagenesis vol. 24 no. 2 p. 173-181.
Claims (25)
- 放射線治療に使用される装置であって、
電離作用を有する放射線を照射するように構成された電離作用発生モジュールと、
電源と、
ユーザ操作用のインターフェースを提供する操作入力用制御部と、
UVA波長、UVB波長およびUVC波長のうちの何れか一つ以上の波長領域に対応する紫外線の照射を行う紫外線照射モジュールと、を備え、
前記電離作用発生モジュールと前記紫外線照射モジュールは、両者同時に又は片方ずつ交互に切り替えながら電離作用を有する前記放射線の照射と前記紫外線の照射を行い、前記電離作用発生モジュールは、少なくとも100ナノメートルより短い波長で放射線を照射する、ことを特徴とする装置。 - 前記電離作用発生モジュールおよび前記紫外線照射モジュールから、電離作用を有する前記放射線の照射と前記紫外線の照射を逐次的に行う、あるいは、前記電離作用発生モジュールおよび前記紫外線照射モジュールから、電離作用を有する前記放射線の照射と前記紫外線の照射を両者同時に行う、請求項1記載の装置。
- 前記電離作用発生モジュールは、陽極、前記陽極と対向するように配置された陰極、および検出器を備える、請求項1または請求項2に記載の装置。
- 前記紫外線照射モジュールは、100ナノメートルから450ナノメートルの範囲内の波長を有する光を発光する光源を備える、請求項1乃至請求項3の何れか一項に記載の装置。
- 電離作用を有する前記放射線は、光子線または粒子線である、請求項1乃至請求項4の何れか一項に記載の装置。
- 電離作用を有する前記放射線は、0.001ナノメートルから10ナノメートルの範囲内の波長を有するX線またはガンマ線である、請求項1乃至請求項5の何れか一項に記載の装置。
- 電離作用を有する前記放射線は、X線である、請求項1乃至請求項6の何れか一項に記載の装置。
- 前記紫外線の照射は、UVA波長およびUVB波長の何れか一方又は両方の波長を含む紫外線照射であり、前記UVA波長および前記UVB波長は、280ナノメートルから400ナノメートルの範囲内の波長領域に対応する、請求項1乃至請求項7の何れか一項に記載の装置。
- 前記紫外線の照射は、315ナノメートルから400ナノメートルの範囲内の波長領域に対応するUVA波長の紫外線照射である、請求項1乃至請求項8の何れか一項に記載の装置。
- 前記紫外線の照射は、280ナノメートルから315ナノメートルの範囲内の波長領域に対応するUVB波長の紫外線照射である、請求項1乃至請求項9の何れか一項に記載の装置。
- 前記紫外線の照射は、100ナノメートルから280ナノメートルの範囲内の波長領域に対応するUVC波長の紫外線照射である請求項1乃至請求項10の何れか一項に記載の装置。
- 対象物を照射する方法であって、
前記対象物の照射に用いる装置を提供する工程であって、前記装置は、電離作用を有する放射線を照射するように構成された電離作用発生モジュールと、UVA波長、UVB波長およびUVC波長のうちの何れか一つ以上の波長領域に対応する紫外線の射を行う紫外線照射モジュールと、電源と、ユーザ操作用のインターフェースを提供する操作入力用制御部と、を備える、第1工程と、
電離作用を有する前記放射線の前記電離作用発生モジュールによる照射と前記紫外線照射モジュールによる前記紫外線の照射を両者同時に又は片方ずつ交互に切り替えながら一定の時間にわたって行う第2工程と、
を備え、前記電離作用発生モジュールは、少なくとも100ナノメートルより短い波長で前記放射線を照射するように構成されている、方法。 - 請求項1乃至請求項11の何れか一項に記載の装置を使用する方法であって、
請求項1乃至請求項11の何れか一項に記載の前記装置を提供する第1工程と、
表面を照射すべき対象物を照射位置に配置する第2工程と、
1分間から48時間の範囲内の継続時間幅にわたって照射を行う工程であって、前記装置が備える前記電離作用発生モジュールおよび前記紫外線照射モジュールによる照射を、両者同時に又は片方ずつ交互に切り替えながら行う第3工程と、を備える方法であり、任意付加的に実行され得る工程として、
電離作用を有する前記放射線の前記電離作用発生モジュールによる照射と前記紫外線照射モジュールによる前記紫外線の照射を少なくとも1回以上繰り返し行う工程と、
電離作用を有する前記放射線の照射および前記紫外線の照射を行う前に、または断続する照射期間の合間において、光化学活性を有する1種類以上の化合物を前記対象物に塗布する工程と、
をさらに備える、方法。 - 前記電離作用発生モジュールからの照射および前記紫外線照射モジュールからの照射を逐次的に行う又は前記電離作用発生モジュールと前記紫外線照射モジュールの両者から同時に照射を行う、請求項13記載の方法。
- 前記電離作用発生モジュールと前記紫外線照射モジュールの両者から同時に行われる照射の継続時間幅は、1分間乃至10分間であり、前記電離作用発生モジュールおよび前記紫外線照射モジュールからの照射を逐次的に行う際の断続的な照射区間の間にある非照射区間の時間幅は5分間乃至48時間である、請求項13または請求項14に記載の方法。
- 前記電離作用発生モジュールおよび前記紫外線照射モジュールのそれぞれによる照射を片方ずつ交互に切り替えながら行う際の個々の連続照射区間の時間幅は、電離作用を有する前記放射線を照射する場合は1分間乃至5分間であり、前記紫外線の照射を行う場合は1分間乃至10分間であり、断続的な照射区間の間にある非照射区間の時間幅は5分間乃至48時間である、請求項13記載の方法。
- 哺乳動物への放射線治療に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む方法。
- 腫瘍の放射線治療に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む方法。
- 疾病の放射線治療に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む方法。
- 急性呼吸窮迫症候群(ARDS)の放射線治療に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む方法。
- 膵臓炎の放射線治療に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む方法。
- 多発性硬化症の放射線治療に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む方法。
- 移植片対宿主病(GVHD)の放射線治療に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む方法。
- 照射対象物の滅菌処理に応用することを目的として、請求項1乃至請求項11の何れか一項に記載の装置を使用する手順、または、請求項13乃至請求項16の何れか一項に記載の方法が備える一つ以上の工程を実行する手順を含む滅菌処理方法。
- 照射対象物の滅菌処理に応用することを目的とする請求項24記載の方法であって、照射対象物の表面の滅菌処理または液体もしくは血液を照射対象物とする滅菌処理を行うための滅菌処理方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1630088-1 | 2016-04-14 | ||
SE1630088 | 2016-04-14 | ||
PCT/SE2017/050374 WO2017180054A1 (en) | 2016-04-14 | 2017-04-13 | An apparatus for use in irradiation therapy comprising ionization module and uv-light source |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019523687A true JP2019523687A (ja) | 2019-08-29 |
JP7175437B2 JP7175437B2 (ja) | 2022-11-21 |
Family
ID=60042188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019506339A Active JP7175437B2 (ja) | 2016-04-14 | 2017-04-13 | 放射線治療に用いる装置 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11351393B2 (ja) |
EP (1) | EP3442653A4 (ja) |
JP (1) | JP7175437B2 (ja) |
CN (1) | CN109414588A (ja) |
AU (2) | AU2017249500A1 (ja) |
BR (1) | BR112018071136A2 (ja) |
RU (1) | RU2018136347A (ja) |
WO (1) | WO2017180054A1 (ja) |
ZA (1) | ZA201806873B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6493703B1 (ja) * | 2017-09-28 | 2019-04-03 | ウシオ電機株式会社 | 殺菌方法、殺菌装置 |
CN109966650A (zh) * | 2017-12-28 | 2019-07-05 | 广东百视特照明电器有限公司 | 一种Led疱疹治疗仪及治疗方法 |
CN111812315A (zh) * | 2019-04-12 | 2020-10-23 | 中国科学院化学研究所 | 药物损伤dna功能化磁性纳米亲和探针及其制备方法和应用 |
CN111044438A (zh) * | 2019-12-31 | 2020-04-21 | 广东博溪生物科技有限公司 | 一种辐射仪 |
CH718557A1 (de) * | 2021-04-21 | 2022-10-31 | Jk Holding Gmbh | Vorrichtung zur Stimulation der Biosynthese von Vitamin D3. |
US11980774B2 (en) * | 2021-08-05 | 2024-05-14 | Know Bio, Llc | Illumination devices and related methods for phototherapeutic light treatments in the presence of vitamins |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001503645A (ja) * | 1995-10-24 | 2001-03-21 | ロスリン メディカル リミテッド | 診断装置 |
JP2001225814A (ja) * | 2000-02-15 | 2001-08-21 | Toyo Seikan Kaisha Ltd | プリフォーム殺菌方法及びプリフォーム殺菌装置 |
US20030161753A1 (en) * | 2001-03-23 | 2003-08-28 | Macphee Martin | Methods for sterilizing biological materials by multiple rates |
JP2005508664A (ja) * | 2001-06-15 | 2005-04-07 | ユーブイ−ソルーションズ・エルエルシー | バンデージを通して領域を滅菌または消毒する方法および器具 |
JP2008039766A (ja) * | 2006-07-10 | 2008-02-21 | Xnet Corp | 光電子銃および殺菌装置 |
JP2008539808A (ja) * | 2005-03-14 | 2008-11-20 | アラクス・メディカル・インコーポレーテッド | 標的の身体表面を介した放射線治療の機器、方法およびキット |
JP2013543628A (ja) * | 2010-07-26 | 2013-12-05 | メルク パテント ゲーエムベーハー | デバイスにおけるナノ結晶 |
JP2015063535A (ja) * | 2008-04-04 | 2015-04-09 | イミュノライト・エルエルシー | insituでのフォトバイオモデュレーションのための非侵襲性システムおよび方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3822410A (en) * | 1972-05-08 | 1974-07-02 | J Madey | Stimulated emission of radiation in periodically deflected electron beam |
IT1119312B (it) * | 1979-06-29 | 1986-03-10 | Fiat Ricerche | Metodo ed apparato per la generazione di radiazione elettromagnetica coerente particolarmente nel campo del lontano ultravioletto e dei raggi x |
US5317514A (en) * | 1992-05-29 | 1994-05-31 | Alliedsignal Inc. | Integrity monitoring of navigation systems using Baye's rule |
US5317574A (en) * | 1992-12-31 | 1994-05-31 | Hui Wang | Method and apparatus for generating x-ray and/or extreme ultraviolet laser |
US6761729B2 (en) * | 2000-12-22 | 2004-07-13 | Advanced Medicalapplications, Inc. | Wound treatment method and device with combination of ultrasound and laser energy |
US7442312B2 (en) * | 2001-08-17 | 2008-10-28 | Trojan Technologies Inc. | Energy-based process for fluid treatment and system thereof |
US6960201B2 (en) * | 2002-02-11 | 2005-11-01 | Quanticum, Llc | Method for the prevention and treatment of skin and nail infections |
US9050116B2 (en) * | 2003-10-14 | 2015-06-09 | Gregg S. Homer | Dermal retraction with intersecting electromagnetic radiation pathways |
US20080058786A1 (en) * | 2006-04-12 | 2008-03-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Autofluorescent imaging and target ablation |
US8976932B2 (en) * | 2010-07-09 | 2015-03-10 | Bsr Co., Ltd. | X-ray generating device |
WO2012170401A2 (en) * | 2011-06-06 | 2012-12-13 | Percuvision, Llc | Sensing catheter emitting radiant energy |
GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
DE102012008812A1 (de) * | 2012-04-25 | 2013-10-31 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Röntgenquelle mit Modul und Detektor für optische Strahlung |
US8951296B2 (en) * | 2012-06-29 | 2015-02-10 | Medtronic Ardian Luxembourg S.A.R.L. | Devices and methods for photodynamically modulating neural function in a human |
WO2015149170A1 (en) * | 2014-03-31 | 2015-10-08 | Functional Neuromodulation, Inc. | Systems and methods for determining a trajectory for a brain stimulation lead |
-
2017
- 2017-04-13 BR BR112018071136A patent/BR112018071136A2/pt active Search and Examination
- 2017-04-13 US US16/093,642 patent/US11351393B2/en active Active
- 2017-04-13 RU RU2018136347A patent/RU2018136347A/ru not_active Application Discontinuation
- 2017-04-13 WO PCT/SE2017/050374 patent/WO2017180054A1/en active Application Filing
- 2017-04-13 CN CN201780023859.6A patent/CN109414588A/zh active Pending
- 2017-04-13 JP JP2019506339A patent/JP7175437B2/ja active Active
- 2017-04-13 EP EP17782749.0A patent/EP3442653A4/en active Pending
- 2017-04-13 AU AU2017249500A patent/AU2017249500A1/en not_active Abandoned
-
2018
- 2018-10-15 ZA ZA2018/06873A patent/ZA201806873B/en unknown
-
2022
- 2022-04-19 AU AU2022202546A patent/AU2022202546B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001503645A (ja) * | 1995-10-24 | 2001-03-21 | ロスリン メディカル リミテッド | 診断装置 |
JP2001225814A (ja) * | 2000-02-15 | 2001-08-21 | Toyo Seikan Kaisha Ltd | プリフォーム殺菌方法及びプリフォーム殺菌装置 |
US20030161753A1 (en) * | 2001-03-23 | 2003-08-28 | Macphee Martin | Methods for sterilizing biological materials by multiple rates |
JP2005508664A (ja) * | 2001-06-15 | 2005-04-07 | ユーブイ−ソルーションズ・エルエルシー | バンデージを通して領域を滅菌または消毒する方法および器具 |
JP2008539808A (ja) * | 2005-03-14 | 2008-11-20 | アラクス・メディカル・インコーポレーテッド | 標的の身体表面を介した放射線治療の機器、方法およびキット |
JP2008039766A (ja) * | 2006-07-10 | 2008-02-21 | Xnet Corp | 光電子銃および殺菌装置 |
JP2015063535A (ja) * | 2008-04-04 | 2015-04-09 | イミュノライト・エルエルシー | insituでのフォトバイオモデュレーションのための非侵襲性システムおよび方法 |
JP2013543628A (ja) * | 2010-07-26 | 2013-12-05 | メルク パテント ゲーエムベーハー | デバイスにおけるナノ結晶 |
Also Published As
Publication number | Publication date |
---|---|
JP7175437B2 (ja) | 2022-11-21 |
US20190126057A1 (en) | 2019-05-02 |
RU2018136347A (ru) | 2020-05-14 |
RU2018136347A3 (ja) | 2020-07-27 |
AU2022202546B2 (en) | 2024-05-09 |
AU2017249500A1 (en) | 2018-11-01 |
ZA201806873B (en) | 2020-03-25 |
EP3442653A1 (en) | 2019-02-20 |
US11351393B2 (en) | 2022-06-07 |
WO2017180054A1 (en) | 2017-10-19 |
CN109414588A (zh) | 2019-03-01 |
BR112018071136A2 (pt) | 2019-02-05 |
AU2022202546A1 (en) | 2022-05-12 |
EP3442653A4 (en) | 2020-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7175437B2 (ja) | 放射線治療に用いる装置 | |
Esplen et al. | Physics and biology of ultrahigh dose-rate (FLASH) radiotherapy: a topical review | |
Montay-Gruel et al. | X-rays can trigger the FLASH effect: Ultra-high dose-rate synchrotron light source prevents normal brain injury after whole brain irradiation in mice | |
US20240042233A1 (en) | Tumor imaging with x-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties | |
Verhaegen et al. | Small animal radiotherapy research platforms | |
Forbes et al. | Phototherapy of human tumours using haematoporphyrin derivative | |
Tillner et al. | Precise image-guided irradiation of small animals: a flexible non-profit platform | |
Mazal et al. | Biological and mechanical synergies to deal with proton therapy pitfalls: minibeams, FLASH, arcs, and gantryless rooms | |
Schültke et al. | A mouse model for microbeam radiation therapy of the lung | |
Nakayama et al. | The history of multimodal treatment of Wilms’ tumor | |
Wang et al. | Ultrasound-induced cell death of nasopharyngeal carcinoma cells in the presence of curcumin | |
Gomer et al. | Expression of potentially lethal damage in Chinese hamster cells exposed to hematoporphyrin derivative photodynamic therapy | |
Breitkreutz et al. | External beam radiation therapy with kilovoltage x-rays | |
Dilmanian et al. | Microbeam radiation therapy: Tissue dose penetration and BANG-gel dosimetry of thick-beams’ array interlacing | |
US20190380669A1 (en) | A unit and equipment for radiotherapeutic preclinical studies | |
Raj et al. | Role of synchrotron radiation in cancer: A review on techniques and applications | |
Liu | A New Method to Investigate RECA Therapeutic Effect | |
Ouar et al. | Monte Carlo simulation of a new proton therapy technique using bio-nanoparticles and high energy proton beams | |
Verhaegen et al. | Developing technologies for small animal radiotherapy | |
Hertsyk et al. | Dvantages of using linear accelerators of new generation for radiation therapy of tumors | |
Li et al. | Photodynamic Therapy Excited by Cerenkov Radiation from Cesium-137 Irradiator: In Vitro Studies | |
RU53574U1 (ru) | Устройство для лечения псориаза | |
Massager et al. | Experimental Analysis of Radiation Dose Distribution in Radiosurgery: I. Dose Hot Spot inside Target Volume: I. Dose Hot Spot inside Target Volume | |
JP6667643B2 (ja) | 窓口を有するフラットpet撮像装置 | |
Tzerkovsky et al. | Experimental in vivo studies of the antitumor efficacy of photodynamic and radiodynamic therapy and their combinations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20181112 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190222 |
|
RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20190226 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190305 |
|
RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20190305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190522 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200413 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210601 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220412 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220822 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220920 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7175437 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |